oasis 1 oral semaglutide 50 mg obesity nejm 2023 of #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. https://ja.ma/41sPiYj In the OASIS 4 phase
Description
DA Meeting News

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging

It operates differently than previous choices
My breasts were left physically deformed after nursing 3 boys, but Dr
